Gordon Fox • June 27, 2023
Patient Education Committee Update

The Patient Education Committee has been busy in recent months! Some of the projects we’re working on or planning include:

Caregiver education :

We will develop guides to help family members, and friends know when patients need help and what steps (emergency room, call the doctor, additional medications) to take if they do.

Decision making:

  • Understanding medical strategies: We will develop materials to help patients understand how doctors make medical decisions. For example, how do they decide to recommend (or not recommend) an ICD implantation or myectomy? And how should patients make their own decisions about these recommendations?
  • Personal decisions that are affected by HCM: Many decisions HCM patients need to make aren’t one-size-fits-all. For example, should I have a child? Should I accept the offer of a job with physical challenges? We will be developing materials aimed at helping think out these decisions by examining their consequences, using decision trees.

There are a number of other things in the hopper. We are discussing ways to use new forums and new approaches to reach people who may have HCM. And in the not-too-distant future, watch for an update on our website! We are always happy to listen to suggestions, whether big (new projects) or small (say, an error on the website).

If there is a resource that you would find helpful, please email  elena@4hcm.org , and she will forward it to the HCMA Patient Education Committee. 

HCMA Blog

A light blue and dark blue paintbrush stroke intersect to make a stylized

Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

By Erica Friedman • June 18, 2025
Alnylam press release on the European Commission approval of AMVUTTRA® (vutrisiran) forwild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication
Light & dark blue brush stroke that intersect create an abstract letter 'a' next to the word Alnylam

Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran) for Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

By Erica Friedman • June 17, 2025
AMVUTTRA® (vutrisiran) has been approved by the U.S. Food and Drug Administration (FDA) to treat ATTR-CM in adults.
A pregnant woman and partner make a heart with their hands over the baby.

HCM in Pregnancy

By Sabrina Cuddy • June 12, 2025
Pregnancy is a stress on the body even for healthy people. When we have a serious disease, we tend to have even more questions. Health Educator Sabrina Cuddy answers some of the most common questions about HCM and Pregnancy.
More Posts